Genomadix Secures First License of CubeX Platform and Divests Legionella Business to LuminUltra LuminUltra to Develop Menu of Portable PCR Products on the CubeX Platform OTTAWA, CANADA, September 9, 2024 – Genomadix (genomadix.com), the global leader in point of care precision medicine molecular diagnostics, today announced that it has licensed its CubeX Open Platform technology […]
Genomadix Eyes Expanded PGx Applications, Out licensing for Rapid PCR System CEO, Steve Edgett, and Chief Scientific Officer, Jeremy Bridge-Cook sit down with GenomeWeb to share some groundbreaking developments at Genomadix. Check out the article below: Genomadix Eyes Expanded PGx Applications, Outlicensing for Rapid PCR System | GenomeWeb
Genomadix Eyes Expanded PGx Applications, Out licensing for Rapid PCR System Read More »
Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion Stanford Medical Center has just introduced the Genomadix Cube and its rapid FDA-cleared CYP2C19 assay to their genomics lab. Check out the article below: Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion | GenomeWeb
Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion Read More »
GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING Spartan Bioscience Inc. (Spartan) announces today that its primary assets will be acquired by a private company owned and led by Casa-Dea Finance Limited (Casa-Dea). In acquiring Spartan’s assets, Casa-Dea will strive to ensure that Spartan’s disruptive technology, and talented team of scientists, engineers and biotech professionals, will
Assets of Spartan Bioscience Inc. To Be Acquired By Casa-Dea Finance Limited Read More »
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM (OTTAWA, March 22, 2023) Genomadix , based in Ottawa, Canada, announced today the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its “Genomadix CubeTM CYP2C19 System” (CubeTM CYP2C19 Test), an automated sample-to-result PCR test. The CubeTM CYP2C19 Test is indicated
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM Read More »
Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic OTTAWA, ON, Aug. 29, 2022 /CNW/ – Genomadix today announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular analyzer technology. The Genomadix CubeTM uses polymerase chain reaction (PCR) technology in a small and portable
Genomadix Inc. Announces Know-How License Agreement With Mayo Clinic Read More »
© 2024 Genomadix, the Genomadix logo and all product names are the property of Genomadix or its licensors. All rights reserved.
External social links open to a new page or tab.
